Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052421 | 1.00 | CA14 (0.33) | CA14KEAP1NFE2L2HCAR2HDAC6 | |
| SCHEMBL14617835 | 0.79 | CA14 (0.36) | CA14KEAP1NFE2L2HCAR2HDAC6 | |
| SCHEMBL1207293 | 0.78 | CA14 (0.39) | CA14HDAC6KCNQ4KCNQ5 | |
| SCHEMBL4872179 | 0.78 | DPP4 (0.39) | CA14HDAC6KCNQ4KCNQ5 | |
| SCHEMBL8644916 | 0.77 | CA14 (0.40) | CA14HDAC6KCNQ4KCNQ5 | |
| SCHEMBL8644921 | 0.77 | CA14 (0.40) | CA14HDAC6KCNQ4KCNQ5 | |
| SCHEMBL4864506 | 0.77 | HDAC6 (0.31) | HDAC6 | |
| SCHEMBL15156121 | 0.76 | HCAR2 (0.39) | CA14KEAP1NFE2L2HCAR2HDAC6 | |
| SCHEMBL14924273 | 0.76 | HCAR2 (0.39) | CA14KEAP1NFE2L2HCAR2HDAC6 | |
| SCHEMBL26498473 | 0.76 | HCAR2 (0.41) | KEAP1NFE2L2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516403-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | Imperial Innovations Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077095-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | ERBB2, EGFR, ERBB4 | CA14 931/4885KEAP1 1469/4885NFE2L2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.